{"id":558,"date":"2011-10-10T04:39:41","date_gmt":"2011-10-10T04:39:41","guid":{"rendered":"https:\/\/drprem.com\/guide\/reseach-on-head-and-neck-cancer-patients\/"},"modified":"2020-05-15T15:53:23","modified_gmt":"2020-05-15T10:23:23","slug":"reseach-on-head-and-neck-cancer-patients","status":"publish","type":"post","link":"https:\/\/drprem.com\/globalhealthcare\/reseach-on-head-and-neck-cancer-patients","title":{"rendered":"Research on head and neck cancer patients"},"content":{"rendered":"
\n<\/a>\n<\/div>\n

<![CDATA[Access Pharmaceuticals, Inc. (OTC:ACCP), announced findings of an independent presentation on MuGard clinical experience. The ongoing research study was conducted by the Oncology and Maxillofacial Departments of the Musgrove Park Hospital in Taunton, UK. In the study, 20 head and neck cancer patients were prospectively assessed for MuGard efficacy and tolerability, and compared to a historical comparison group of head and neck cancer patients.<\/p>

\n<\/a>\n<\/div>\n\n

MuGard was effective in prevention, delay and management of radiotherapy (RT) and chemo-radiotherapy (C-RT) induced oral mucositis, as well as reducing the need for opiate pain medicine and gastrostomy (feeding tube) use. Patients using MuGard noted a reduction of the severity of both clinically assessed and patient perceived symptoms of oral mucositis, resulting in RTOG scoring (the Radiation Therapy Oncology Group assessment score) falling to half of expected value.<\/p>\n

Ref and Read more: https:\/\/biomedreports.com\/2011092979604\/access-pharma-reports-additional-mugard-study-findings-onyx-submits-new-drug-application-for-carfilzomib.html]]> \t<\/p>\n

\n

\r\n <\/a><\/p>\r\n